No matter where you live, you can support the access of Australians with CLL to Acalabrutinib or Venetoclax treatment. Australia's Pharmaceutical Benefits Advisory Committee (PBAC) is soon assessing Acalabrutinib or Venetoclax for listing - which would make them an affordable treatment for Australians with CLL. Given Venetoclax came out of Australian research done at Melbourne's Walter and Eliza Hall Institute of Medical Research, originating from a discovery there of the importance of the BCL-2 regulator protein in haematological malignancies in the late 1980s and supported by Leukaemia Foundation research funding grants, it would be particularly fitting to have Venetoclax approved!
Submissions can be done directly to the PBAC via this form for Australians: www1.health.gov.au/internet... or via Australia's Leukaemia Foundation here: leukaemiafoundation.typefor... The Leukaemia Foundation submission form doesn't require you to provide your address and phone number and also avoids the problems with overseas Zip/Post codes, but does ask for an Australian state. I suggest using ACT (Australian Capital Territory, which is our equivalent to the USA's Washington DC.
As Australia's Leukaemia Foundation says, "Whether you're a person with blood cancer, a friend or family member or a health care professional, we want your voice to be heard. Tell us about you or your loved ones experience with the drugs or blood cancers listed in the feedback form and we'll add that to our submission to the Pharmaceutical Benefits Advisory Committee (PBAC), They are meeting in July 2020 to assesses medicines for listing on the Pharmaceutical Benefits Advisory Scheme (PBS). Feedback closes 5pm (AEST) Monday 1 June 2020."
Having access to non-infusion based treatments is particularly important in our post SARS coronavirus world, reducing the risk of exposure through hospital attendance. Even with Venetoclax, only a proportion of those treated need to be observed in a hospital setting during the ramp-up phase, with the need for such observation further reduced if the tumour burden has been reduced by other drugs. Non-infusion based treatments are also a boon for those of us living a long way from treatment centres.
On behalf of all Australians living with CLL, thank you for your support.
This is an unlocked post for obvious reasons! healthunlocked.com/cllsuppo...